Bioventus Inc. Acquires Misonix, Inc.

Bioventus Acquires Bioness, Inc.

March 30, 2021

Medical Devices

Bioventus Inc. acquired Bioness, Inc. for $45 million in up-front consideration plus up to $65 million of contingent consideration, making Bioness a wholly‑owned subsidiary. The acquisition expands Bioventus' rehabilitation and neuromodulation product portfolio and R&D pipeline, and is expected to be accretive to revenue by leveraging Bioventus' global commercial infrastructure.

Bioventus Acquires CartiHeal for $500M

August 30, 2021

Medical Devices

Nasdaq-traded Bioventus has elected to exercise its option to acquire Israel-based medical device company CartiHeal following FDA approval of the Agili-C implant, in a deal valued at approximately $500 million. Bioventus plans to work with the CartiHeal team on commercialization and reimbursement activities to bring Agili-C to market.

Accelmed Partners Acquires Bioventus' Bioness Advanced Rehabilitation Business

October 1, 2024

Medical Devices

Bioventus has signed a definitive agreement to sell the Advanced Rehabilitation business of its subsidiary Bioness to private equity firm Accelmed Partners for total cash consideration of $45 million (including up to $20 million in earn-outs). The divestiture reduces Bioventus' annual revenue by about $50 million and allows Bioventus to focus on its core business while Accelmed plans to invest in and expand the Bioness rehabilitation product line.

BioStem Technologies Acquires BioTissue's Surgical and Wound Care Business

January 22, 2026

Medical Devices

BioStem Technologies (OTC: BSEM) has acquired the surgical and wound care business of BioTissue Holdings, Inc. for approximately $15 million upfront, with up to $25 million of contingent milestone and royalty payments. The deal includes the Neox and Clarix product lines, a nationwide commercial sales organization and assigned GPO contracts, expanding BioStem's access into hospital inpatient and outpatient wound-care markets and adding assets that generated roughly $29 million in 2025.

BioVie Acquires Biopharma Assets of NeurMedix

June 11, 2021

Pharmaceuticals

BioVie Inc. acquired the biopharmaceutical assets of privately held NeurMedix, including NE3107, an orally administered small-molecule inhibitor targeting neuroinflammation and insulin resistance. The deal paid NeurMedix shareholders newly issued BioVie shares and cash at closing, with additional contingent cash and equity payments tied to clinical and regulatory milestones; the acquisition expands BioVie's pipeline into neurodegenerative diseases and oncology.

Hologic Acquires Gynesonics

January 6, 2025

Medical Devices

Hologic has completed the acquisition of Gynesonics for approximately $350 million. The purchase adds the Sonata System — a minimally invasive intrauterine ultrasound-guided radiofrequency ablation platform for treating uterine fibroids — to Hologic's portfolio, expanding its capabilities in women's health surgical solutions.